Carmela Pisano

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 392 citations

Medicine, Gynecology, Oncology +12

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina et al. · Journal of Clinical Oncology · 2011 · 227 citations · Full text

Medicine, Oncology, Pharmacology +13

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Sandro Pignata, Domenica Lorusso, Giovanni Scambia et al. · The Lancet Oncology · 2015 · 172 citations · Full text

Medicine, Oncology, Pharmacology +13

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri et al. · Annals of Oncology · 2024 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 149 citations

Medicine, Gynecology, Oncology +15